All News
Best of 2023: Cost-Effective Use of Biological and Targeted Synthetic DMARDs
An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).
Read Article
Best of 2023: 25 Great Women in Rheumatology
This week I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized? This was prompted by a smart article in Annals of Rheumatic Disease written by Drs. Tuhina Neogi (Boston) and Nicola Dalbeth (N. Zealand), entitled "Where are the women ‘Heroes and Pillars of Rheumatology’?
Read Article
Do I have Arthritis?
How I handle this frequent curbside consult question...
https://t.co/uX6MUfy59w https://t.co/kYviOhcLQj
Dr. John Cush RheumNow ( View Tweet)
Marketscan claims data shows Frailty as predictor for serious infxn in RA pts Rx w/ b/tsDMARDs. Among 57,980 RA pts (age 48 yrs), 6% were "frail" - this assoc w/ increased risk of serious infections (aHR 1.5) & inpatient hosp (1.4)https://t.co/cvcqE3KQmV https://t.co/We9uwMdt5Y
Dr. John Cush RheumNow ( View Tweet)
FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/XdQ3D2McTF https://t.co/wnusToyZTG https://t.co/w8ooCCGrI0…
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid vasculitis (RV) metanalysis: RV decreased from 9.1 (1988-2000) to 3.9 (2001-2010) per million. RV risk increased w/ smoking, disease duration, seropositivity, males, HLA-DRB104, HLA-C3. Common: skin (65–88%), CNS(35–63%), cardiac (33%) https://t.co/gBxd9EIvo2 https://t.co/NFMSkeAq5d
Dr. John Cush RheumNow ( View Tweet)
A double-blind, sham-controlled RCT of auricular vagus nerve stimulation (VNS) showed NO meaningful improvement in 101 RA completers. @week 12, ACR20 was 25% for VNS vs 27% for sham (NS). Also NS was change in DAS28-CRP (–0.95 vs –0.66)(p 0.06) https://t.co/n4e564a3gN https://t.co/mnVliEuafK
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live 2024 is nearly here!
Among our 25 speakers, Dr. Weber will cover Cardio-Rheumatology Clinic - Identifying CV Risks. Dr. Guma will cover Nutrition in RA. Dr. El Gabalaway will cover the Prevention of RA, all in a session on Success in RA.
https://t.co/5kq9KReEsJ https://t.co/L2GiR8Upqn
Links:
Dr. John Cush RheumNow ( View Tweet)
Best of 2023: Cost-Effective Use of Biological and Targeted Synthetic DMARDs
An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease.
https://t.co/UAlpww3fmi https://t.co/NpkTgwDuRl
Dr. John Cush RheumNow ( View Tweet)
Time to Risk Stratify Methotrexate Lab Monitoring? A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy. https://t.co/R2TOzSO6cx https://t.co/XY3XEkSCT6
Dr. John Cush RheumNow ( View Tweet)
RA and cancer risk in the biologic era
RA is known to be historically associated with site specific cancers, especially lung skin and lymphomas. This risk was described as likely to be supported by chronic systemic inflammation before the biologic era.
https://t.co/ZOWFKTg3l3 https://t.co/1VLWgxVb0W
Dr. John Cush RheumNow ( View Tweet)
STOP-RA study on HCQ preventing RA... HCQ did NOT prevent RA development in pre-RA pts
#RNL2023 https://t.co/BqZlajMOLK https://t.co/Omui3LWiPi
Links:
Dr. John Cush RheumNow ( View Tweet)
Analysis of 14,958 RA pts in Japans National Database of Rheumatic Diseases (NinJa) shows women had higher DAS28-ESR values than males, despite no obvious difference in other indices or disease activity categories. https://t.co/bLFmRdulCw
Dr. John Cush RheumNow ( View Tweet)
A Danish national registry study compared RA pts taking JAKi (n 875) and bDMARDs (n 4247). They found similar rates of subsequent cancers (14.4 vs 12.9/ per 1000 PYRS); with a nonsignificant risk (HR1.41; CI 0.76, 2.37) https://t.co/LNIqQxQFKK
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/AJD4uOS9hz https://t.co/8bmyTUWyFs https://t.co/6IYjk0XUJq https://t.co/OfjdvJZciB
Links:
Dr. John Cush RheumNow ( View Tweet)
200 Biologic naive #RA pts in remission under csDMARD tapering and withdrawal while given either placebo or oral curcumin (1 g bid). Flare-free survival at 52 wks was similar between groups (60% vs 64%; p = 0.76). Time to flare was similar (219d vs 214d) https://t.co/m3j8HmjTT3 https://t.co/jDoAYN0eKQ
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Effective Treatments for Rheumatoid Arthritis ILD
The ACR guidelines for the diagnosis and management of interstitial lung disease, which includes RA-ILD, has been one of the most controversial topics in the runup to ACR Convergence.
https://t.co/tvXEeaTbRq https://t.co/Dq3NcSAGhf
Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study 365 RA pts showed eating half a pizza >1 time/wk (vs. ≤2 times/mo) was assoc w/ 70% less Dz activity; esp w/ more severe RA (80%) (benefit likely due to mozzarella & olive oil). YES, this was an italian study... https://t.co/1yHtS1wrtn https://t.co/xoxKK6ujdk
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Eosinophilia in RA
High Eosinophil counts in Stable RA - what's the differential Dx?.
https://t.co/r7DHil4u9B https://t.co/rTAGUcgd1C
Dr. John Cush RheumNow ( View Tweet)
RA pts more likely to get autoimmune thyroid Dz (AITD), but after dx, AITD risk signif. drops (HR 0.81), suggesting RA Rx lowers AITD risk; greater drop in biologic Rx RA (HR 0.54).Swiss registry compared 13,731 new-onset RA pts to 63,201 matched controls https://t.co/iBIreoNrXx https://t.co/xh4rWdKbGT
Dr. John Cush RheumNow ( View Tweet)
